GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Revenue increased 11.4 per cent to Rs. 8,545 crore
Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
Subscribe To Our Newsletter & Stay Updated